《新股表現》醫脈通(02192.HK)暗盤高開28.5%報34.95元
根據輝立交易平臺顯示,明天掛牌的醫脈通(02192.HK)暗盤高開28.5%報34.95元,最高見35元遇壓,曾回順至31元,現造32.2元,較上市價27.2元,高逾18%,成交132萬股。
根據弗若斯特沙利文報告,按截至去年底註冊醫師用戶數目計,醫脈通是內地最大在線專業醫師平臺,其自主開發的醫脈通平臺也廣獲中國醫師認可,並已成爲最受歡迎專業醫療平臺。是次在港上市共發售逾1.55億股,並已引入包括FMR、富達國際、騰訊(00700.HK)全資附屬Tencent Mobility及GIC、Matthews Funds、Springhill及OrbiMed Funds七名基石投資者,合共認購6,278.45萬股;其中10%公開發售獲逾591倍超購,已啓動回撥機制佔比增至50%,認購一手中籤率僅5%;股份以招股範圍(24.1-27.2)上限定價,料集資淨額約40.01億元,主要用作未來三至五年內擴展業務及投資技術和提高研發能力、用於有精心挑選戰略投資或收購機會等。上市聯席保薦人分別爲高盛及海通國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.